AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019PBPK modelling and simulation of ritonavir-boosted atazanavir (ATV/r) dosing when co-administered with rifampicin (RIF)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Alteration of hepatic OATP activity does not alter the pharmacodynamic effect of GS-0976, a liver targeted ACC inhibitor, on de novo lipogenesisView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacokinetic (PK) and pharmacocokinetic/pharmacodynamic characterization of the two-drug anti-retroviral regimen (2DR) dolutegravir/rilpivirine following switch from current anti-retroviral therapy in the SWORD-1 and SWORD-2 Phase 3 studiesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Characterization of binding of dolutegravir to plasma proteinsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Antiretroviral penetration and drug transporter concentrations in the spleens of three preclinical animal models and humansView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at a referral hospital in EthiopiaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Temsavir concentration (Cp)-QTc relationship following administration of fostemsavirView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Plasma and intracellular pharmacokinetics of cobicistat in the clinical settingView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Proficiency testing supports combined analysis of dolutegravir pharmacokinetic dataView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacokinetics of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in a client on PrEP after a total gastrectomy with Roux and Y anastomosis (TGRY).View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Management of antiretrovirals in seniors: the importance of assisted treatment for adherence to treatmentView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of CabotegravirView Abstract
